Using GnRHa for luteal phase support in infertility treatments
Gonadotropin Releasing Hormone Agonist for Luteal Phase Support in Gonadotropin Releasing Hormone Antagonist Protocol Cycles
This study is testing if adding a single dose of a hormone treatment can help women undergoing fertility treatments have better chances of getting pregnant after embryo transfer.
Quick facts
| Phase | Phase 4 |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 20 Years to 38 Years |
| Sex | Female |
| Sponsor | Mansoura University Academic / other |
| Locations | 2 sites (Mansourah, Dakahlia and 1 other locations) |
| Trial ID | NCT02312089 on ClinicalTrials.gov |
What this trial studies
This study evaluates the impact of adding a single dose of gonadotropin-releasing hormone agonist (GnRHa) to luteal phase support in women undergoing intracytoplasmic sperm injection (ICSI) after controlled ovarian hyperstimulation with GnRH antagonists. Participants will be randomly assigned to receive either the GnRHa treatment or standard luteal phase support with progesterone and estradiol. The aim is to determine if the addition of GnRHa improves pregnancy outcomes following embryo transfer. The study will assess the effectiveness of this approach in enhancing reproductive success.
Who should consider this trial
Good fit: Ideal candidates are women undergoing ICSI with controlled ovarian hyperstimulation using GnRH antagonists.
Not a fit: Patients with moderate or severe endometriosis, hydrosalpinx, uterine abnormalities, myoma, or previous uterine surgery may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could improve pregnancy rates for women undergoing ICSI treatments.
How similar studies have performed: Other studies have shown promising results with similar approaches, indicating potential for success.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Women subjected to ICSI through controlled ovarian hyperstimulation (COH) with pituitary downregulation by GnRH antagonist. Exclusion Criteria: * Moderate or severe endometriosis. * Hydrosalpinx. * Uterine abnormalities. * Myoma. * Previous uterine surgery.
Where this trial is running
Mansourah, Dakahlia and 1 other locations
- Fertility Care Unit (FCU) in Mansoura University Hospital — Mansourah, Dakahlia, Egypt (Recruiting)
- Private fertility care centers — Mansourah, Dakahlia, Egypt (Recruiting)
Study contacts
- Principal investigator: Mohamed S Abdelhafez, Dr — Mansoura University
- Study coordinator: Mohamed S Abdelhafez, Dr
- Email: msabdelhafez@gmail.com
- Phone: +201144523366
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.